HUE061862T2 - Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease - Google Patents

Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease

Info

Publication number
HUE061862T2
HUE061862T2 HUE14779186A HUE14779186A HUE061862T2 HU E061862 T2 HUE061862 T2 HU E061862T2 HU E14779186 A HUE14779186 A HU E14779186A HU E14779186 A HUE14779186 A HU E14779186A HU E061862 T2 HUE061862 T2 HU E061862T2
Authority
HU
Hungary
Prior art keywords
chronic
diuretics
potassium
reduction
treatment
Prior art date
Application number
HUE14779186A
Other languages
Hungarian (hu)
Inventor
Donald Jeffrey Keyser
Alvaro F Guillem
Original Assignee
Zs Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51654632&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE061862(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zs Pharma Inc filed Critical Zs Pharma Inc
Publication of HUE061862T2 publication Critical patent/HUE061862T2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Geology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE14779186A 2013-04-05 2014-04-03 Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease HUE061862T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808897P 2013-04-05 2013-04-05
US201361914362P 2013-12-10 2013-12-10
US201461930331P 2014-01-22 2014-01-22

Publications (1)

Publication Number Publication Date
HUE061862T2 true HUE061862T2 (en) 2023-08-28

Family

ID=51654632

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14779186A HUE061862T2 (en) 2013-04-05 2014-04-03 Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease

Country Status (22)

Country Link
US (3) US20160051584A1 (en)
EP (1) EP2981272B1 (en)
JP (1) JP6280636B2 (en)
KR (1) KR102308673B1 (en)
CN (1) CN105473151B (en)
AU (1) AU2014248081B2 (en)
BR (1) BR112015025438B1 (en)
CA (1) CA2908641C (en)
CL (1) CL2015002951A1 (en)
DK (1) DK2981272T3 (en)
ES (1) ES2943007T3 (en)
FI (1) FI2981272T3 (en)
HK (1) HK1221177A1 (en)
HU (1) HUE061862T2 (en)
IL (1) IL241926B (en)
MX (1) MX2015014055A (en)
PH (1) PH12015502301A1 (en)
PL (1) PL2981272T3 (en)
PT (1) PT2981272T (en)
TW (1) TW201521746A (en)
WO (1) WO2014165670A1 (en)
ZA (1) ZA201507666B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3246287A1 (en) 2011-02-11 2017-11-22 ZS Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
CN114917247B (en) * 2022-05-18 2024-01-26 广东省疾病预防控制中心 Application of nano titanium dioxide in preventing and treating kidney injury

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601398D0 (en) * 1996-01-24 1996-03-27 Piper Edwina M Composition
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
AU2000260501A1 (en) * 2000-07-12 2002-01-21 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US20040105895A1 (en) * 2001-02-06 2004-06-03 Ash Stephen R Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) * 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
WO2010022383A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20120070468A1 (en) * 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
EP3246287A1 (en) * 2011-02-11 2017-11-22 ZS Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
CN104968336A (en) 2012-07-11 2015-10-07 Zs制药公司 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
JP6423795B2 (en) * 2012-10-22 2018-11-14 ズィーエス・ファーマ,インコーポレーテッド Microporous zirconium silicate for the treatment of hyperkalemia

Also Published As

Publication number Publication date
CN105473151A (en) 2016-04-06
PH12015502301A1 (en) 2016-02-10
JP6280636B2 (en) 2018-02-14
WO2014165670A1 (en) 2014-10-09
JP2016515624A (en) 2016-05-30
US20140302175A1 (en) 2014-10-09
FI2981272T3 (en) 2023-05-03
EP2981272B1 (en) 2023-03-01
US20160051584A1 (en) 2016-02-25
IL241926B (en) 2020-10-29
ES2943007T3 (en) 2023-06-08
EP2981272A1 (en) 2016-02-10
CN105473151B (en) 2018-09-18
CL2015002951A1 (en) 2016-11-11
TW201521746A (en) 2015-06-16
US20180271902A1 (en) 2018-09-27
DK2981272T3 (en) 2023-05-01
BR112015025438B1 (en) 2022-06-07
BR112015025438A2 (en) 2017-07-18
PT2981272T (en) 2023-05-03
EP2981272A4 (en) 2016-12-07
HK1221177A1 (en) 2017-05-26
AU2014248081B2 (en) 2019-02-28
KR102308673B1 (en) 2021-10-01
CA2908641C (en) 2022-10-18
PL2981272T3 (en) 2023-05-29
KR20150140750A (en) 2015-12-16
MX2015014055A (en) 2015-12-15
ZA201507666B (en) 2019-09-25
US10695366B2 (en) 2020-06-30
CA2908641A1 (en) 2014-10-09
AU2014248081A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
HK1216421A1 (en) Therapeutic compounds for the treatment of viral infections
HK1223616A1 (en) Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections hiv
HK1246295A1 (en) Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
IL240765A0 (en) Macrocyclic deaza-purinones for the treatment of viral infections
HUE059914T2 (en) Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
ZA201603171B (en) Microporous zirconium silicate for the treatment of hyperkalemia
IL245525A0 (en) Microporous zirconium silicate for the treatment of hyperkalemia
ZA201601351B (en) Organophosphates for treating afflictions of the skin
HK1222794A1 (en) Methods for the prevention or treatment of left ventricle remodeling
EP3013834A4 (en) Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
HK1221177A1 (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and or chronic heart disease
EP3013334A4 (en) Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
EP3021873A4 (en) Methods for the treatment of inflammatory joint disease
HK1221681A1 (en) Methods for the treatment of neurodegeneration
EP2943593A4 (en) Diagnosis and treatment of viral diseases
EP2953473A4 (en) Cell therapy for the treatment of neurodegeneration
HK1223280A1 (en) Human plgf-2 for the prevention or treatment of heart failure plgf-2